利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

114 条记录 (耗时 0.053 秒)

    Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
    51.
    发明授权
    Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery 有权
    通过表达靶向基因递送在COX-2过表达癌细胞中导向细胞凋亡

    公开(公告)号：US07638331B2

    公开(公告)日：2009-12-29

    申请号：US11023020

    申请日：2004-12-23

    申请人： W. Terrance Godbey ,  Anthony Atala

    发明人： W. Terrance Godbey ,  Anthony Atala

    IPC分类号： C12N15/00 ,  C12N15/06 ,  C12N15/11 ,  C12N15/86 ,  C12N15/87

    CPC分类号： C12N9/6475 ,  A61K48/00 ,  C07K14/4747

    摘要： The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked to at least one AIG such that the COX-2 promoter is activated in cells that overexpress COX-2, thereby resulting in transcription and translation of the AIG, which in turn activates apoptosis in the cell. Thus, apoptosis is selectively induced in only those cells capable of overexpressing COX-2.

    摘要翻译： 本发明提供了在过表达环氧合酶-2（COX-2）的细胞群中选择性表达凋亡诱导基因（AIG）以诱导细胞凋亡的方法和构建体。 为了实现该目的，使用嵌合基因构建体，其包含可操作地连接至少一个AIG的环加氧酶-2启动子（COX-2启动子），使得COX-2启动子在过表达COX-2的细胞中被活化，由此 导致AIG的转录和翻译，其依次激活细胞中的细胞凋亡。 因此，只有那些能够过表达COX-2的细胞才能选择性诱导细胞凋亡。

    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE
    52.
    发明申请
    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE 审中-公开
    用于治疗失败的选择性细胞治疗

    公开(公告)号：US20080305146A1

    公开(公告)日：2008-12-11

    申请号：US12134813

    申请日：2008-06-06

    申请人： Anthony Atala ,  James J. Yoo

    发明人： Anthony Atala ,  James J. Yoo

    IPC分类号： A61F2/00 ,  C12N5/06 ,  A61P7/00 ,  A61K35/12

    CPC分类号： C12N5/0686 ,  A61K9/0024 ,  A61K35/12 ,  A61K35/22 ,  C12N2500/02 ,  C12N2502/256 ,  G01N15/1031 ,  G01N33/56966 ,  G01N2015/0065 ,  G01N2015/1081

    摘要： Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.

    摘要翻译： 本文提供从肾分化细胞收获的分离的肾细胞群体，其中细胞已经在体外扩增。 肾细胞可以包括肾的肾周间质细胞，并且优选产生促红细胞生成素（EPO）。 也可以基于EPO生产来选择肾细胞。 还提供了产生分离的EPO产生细胞群体的方法，并且提供了在有需要的患者中治疗导致EPO产生减少的肾脏疾病的方法，包括向患者施用群体，由此细胞在体内产生EPO 。

    Methods and compositions for organ decellularization
    53.
    发明授权
    Methods and compositions for organ decellularization 有权
    器官去细胞化的方法和组成

    公开(公告)号：US06753181B2

    公开(公告)日：2004-06-22

    申请号：US10091665

    申请日：2002-03-05

    申请人： Anthony Atala

    发明人： Anthony Atala

    IPC分类号： A61L27/00 ,  A61L27/36 ,  A61L27/38 ,  C12N5/02

    CPC分类号： A61L27/3691 ,  A61L27/3604 ,  A61L27/3687 ,  A61L27/38 ,  A61L2430/26 ,  A61L2430/40

    摘要： The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.

    摘要翻译： 本发明涉及用于产生脱细胞器官或器官的一部分的方法。 使用机械搅拌的分离的器官产生脱细胞器官，以除去分离的器官周围的细胞膜，而不破坏器官的间质结构。 在移除细胞膜之后，将分离的器官暴露于提取细胞材料而不溶解器官的间质结构的增溶液中。 洗涤液用于去除溶解的组分，留下脱细胞的器官。

    Tissue engineered testicular prosthesis and use thereof
    54.
    发明授权
    Tissue engineered testicular prosthesis and use thereof 失效
    组织工程睾丸假体及其用途

    公开(公告)号：US06620203B2

    公开(公告)日：2003-09-16

    申请号：US10017921

    申请日：2001-12-13

    申请人： Anthony Atala

    发明人： Anthony Atala

    IPC分类号： A61F236

    CPC分类号： A61L27/3839 ,  A61F2/0059 ,  A61F2/02 ,  A61F2/022 ,  A61K35/12 ,  A61L27/18 ,  A61L27/3804 ,  A61L27/3817 ,  A61L27/3886 ,  A61L27/58 ,  C12N5/0697 ,  C12N2502/1317 ,  C12N2502/246 ,  C12N2533/40 ,  C08L67/04

    摘要： The present invention provides a tissue engineered testicular prosthesis for implanting within a patient having a scaffold with a biodegradable polymer scaffold having a substantially elliptical body in longitudinal cross-section replicating the shape of a testicle and a substantially circular cross-section in transverse cross-section, the biodegradable scaffold defining an interior and an exterior of the prosthesis, and the scaffold being seeded with disassociated chondrocytes or Leydig cells, or both chondrocytes and Leydig cells. The interior of the prosthesis can be at least partially filled with testosterone.

    摘要翻译： 本发明提供了一种组织工程睾丸假体，用于植入患有具有可生物降解的聚合物支架的患者的患者，所述支架具有基本上椭圆形的纵向截面，复制睾丸的形状和横截面的基本圆形的横截面 ，所述可生物降解的支架限定假体的内部和外部，并且所述支架用解离的软骨细胞或Leydig细胞，或软骨细胞和Leydig细胞接种。 假体的内部可以至少部分地被睾酮填充。

    Bladder reconstruction
    55.
    发明授权
    Bladder reconstruction 有权
    膀胱重建

    公开(公告)号：US06576019B1

    公开(公告)日：2003-06-10

    申请号：US09600455

    申请日：2000-07-17

    申请人： Anthony Atala

    发明人： Anthony Atala

    IPC分类号： A61F212

    CPC分类号： A61F2/042 ,  A61L27/18 ,  A61L27/3804 ,  A61L27/3813 ,  A61L27/3826 ,  A61L27/383 ,  A61L27/3839 ,  A61L27/3882 ,  A61L27/3891 ,  A61L2430/22 ,  C08L67/04

    摘要： The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material.

    摘要翻译： 本发明涉及用于需要这种治疗的患者中重叠，修复，增加或替换层状组织的腔内器官或组织结构的方法和装置。 该装置包括生物相容的合成或天然聚合物基质，其被成形为与第一区域上或第一区域中的第一细胞群体和第二细胞群体例如平滑肌细胞群体中的至少一部分管腔器官或组织结构一致 聚合物基质的第二区域。 该方法包括将装置移植到患者需要治疗的区域。 聚合物基质包括生物相容性和可生物降解的材料。

    Neomorphogenesis of urological structures in vivo from cell culture
    57.
    发明授权
    Neomorphogenesis of urological structures in vivo from cell culture 失效
    细胞培养体内泌尿结构的新形态

    公开(公告)号：US5851833A

    公开(公告)日：1998-12-22

    申请号：US692243

    申请日：1996-08-07

    申请人： Anthony Atala

    发明人： Anthony Atala

    IPC分类号： A61F2/06 ,  A61L27/38 ,  C12N5/00 ,  A61F2/00 ,  A61F13/00

    CPC分类号： A61L27/3804 ,  A61F2/062 ,  A61L27/3882 ,  C12N5/0068 ,  C12N2533/40

    摘要： Methods and artificial matrices for the growth and implantation of urological structures and surfaces are disclosed in which urothelial cells are grown in culture on biodegradable, biocompatible, fibrous matrices formed of polymers, such as polyglycolic acid, polylactic acid, or other polymers which degrade over time. The cells can be cultured in vitro until an adequate cell volume and density has developed for the cells to survive and proliferate in vivo. Alternatively, when adequate cell numbers for implantation are available, the cells can be attached to the matrix and implanted directly, without proliferation in vitro. The implants approximate the desired urological structure to be replaced or repaired, such as the kidney, urether, bladder, urethra, and the like. Implantation is followed by remodeling through cell growth and proliferation in vivo. In another aspect of the invention, techniques are disclosed for selectively extracting or harvesting urothelial cells either from excised urological tissue in vitro or from intact urological tissue in vivo by treating the tissue with a digestive enzyme, such as collagenase.

    摘要翻译： 公开了用于生长和植入泌尿结构和表面的方法和人造基质，其中尿素上皮细胞在可生物降解的生物相容性的生物相容的纤维基质上生长培养，所述生物相容性由聚合物形成，例如聚乙醇酸，聚乳酸或其它随时间降解的聚合物 。 细胞可以在体外培养，直到细胞体积和密度发展得足以使细胞在体内存活和增殖。 或者，当有足够的用于植入的细胞数目可用时，可以将细胞附着于基质并直接植入，而不会在体外增殖。 植入物近似于要更换或修复的所需泌尿结构，例如肾，尿管，膀胱，尿道等。 植入之后，通过体内细胞生长和增殖重塑。 在本发明的另一方面，公开了用于通过用消化酶（例如胶原酶）处理组织来从体外从切除的泌尿组织或体内完整泌尿组织中选择性提取或收获尿路上皮细胞的技术。

    Breast tissue engineering
    58.
    发明授权
    Breast tissue engineering 失效
    乳腺组织工程

    公开(公告)号：US5716404A

    公开(公告)日：1998-02-10

    申请号：US358189

    申请日：1994-12-16

    申请人： Joseph P. Vacanti ,  Anthony Atala ,  David J. Mooney ,  Robert S. Langer

    发明人： Joseph P. Vacanti ,  Anthony Atala ,  David J. Mooney ,  Robert S. Langer

    IPC分类号： C12N5/06 ,  A61L27/00 ,  A61L27/38 ,  C12N5/08 ,  A61F2/12

    CPC分类号： A61L27/3804 ,  A61F2/12 ,  A61L27/3839 ,  A61F2002/0086 ,  A61F2250/0003 ,  A61L2430/04

    摘要： Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.

    摘要翻译： 本文描述了用于重建或增加乳腺组织的方法和组合物。 离解的细胞，优选肌肉细胞，与合适的可生物降解的聚合物基质组合植入以形成新的组织。 可以使用两种形式的基质：由具有悬浮于其中的细胞的诸如藻酸盐的材料形成的聚合物水凝胶和具有约100至300微米间隙的纤维基质。 优选的聚合物材料是在约一至两个月内降解的物质，例如聚乳酸 - 乙醇酸共聚物。 可以在植入或植入之前将基质接种，允许血管化，然后用细胞接种。 在优选实施例中，细胞 - 基质结构与组织扩张器装置组合植入。 随着细胞基质被植入，或细胞增殖并形成新的组织，扩张器尺寸减小，直到其被去除并且获得所需的重建或增加。 优选的细胞类型是肌肉细胞，尽管可以使用其他类型的间充质细胞，成纤维细胞，软骨细胞和脂肪细胞。 从组织如阴唇获得的细胞可用于特殊应用，例如形成乳头型组织。 其他材料，例如增强植入组织的血管形成和/或抑制纤维化组织向内生长的生物活性分子可以用基质植入以增强更正常组织的发育。